➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Mallinckrodt
Express Scripts
Moodys
Boehringer Ingelheim

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Insulin glargine recombinant - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for insulin glargine recombinant

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Boston Medical CenterPhase 3
Jawaharlal nehru institute of medical education and research PuducherryPhase 4
Hinduja hospitals mumbaiPhase 4

See all insulin glargine recombinant clinical trials

Recent Litigation for insulin glargine recombinant

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
SANOFI-AVENTIS U.S. LLC v. MYLAN N v.2017-10-24
SANOFI-AVENTIS U.S. LLC v. MERCK SHARP & DOHME CORP.2017-08-08
Allergan Sales, LLC v. Teva Pharmaceuticals USA, Inc.2016-11-30

See all insulin glargine recombinant litigation

PTAB Litigation
PetitionerDate
Pfizer Inc.2019-05-02
Mylan Pharmaceuticals Inc.2018-10-29
Mylan Pharmaceuticals Inc2018-09-10

See all insulin glargine recombinant litigation

Company Disclosures: US Patents for insulin glargine recombinant

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Medimpex Ets. (Balzers, LI) 2012-02-21 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Medimpex Ets (LI) 2013-04-23 RX company
Sanofi Aventis Us LANTUS insulin glargine recombinant INJECTABLE;INJECTION 021081 001 2000-11-17   Start Trial Hoechst Aktiengesellschaft (Frankfurt am Main, DE) 2014-08-12 RX company
Sanofi Aventis Us LANTUS SOLOSTAR insulin glargine recombinant INJECTABLE;INJECTION 021081 002 2000-11-17   Start Trial Medimpex Ets. (Balzers, LI) 2012-02-21 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for insulin glargine recombinant

These patents were identified by searching patent claims

Supplementary Protection Certificates for insulin glargine recombinant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0009 France   Start Trial PRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE: EU/1/04/285/001 20040929
91020-8 0090020-9 Sweden   Start Trial PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 20000609
0170 Netherlands   Start Trial PRODUCT NAME: INSULINE-GLULISINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/04/285/002 20040928
2013000061 Germany   Start Trial PRODUCT NAME: INSULIN DEGLUDEC IN ALLEN DURCH DAS BASISPATENT GESCHUETZTEN FORMEN; REGISTRATION NO/DATE: EU/1/12/807/001 EU/1/12/807/004-005 EU/1/12/807/007-009 EU/1/12/807/012-013 EU/1/12/807/015 20130121
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Johnson and Johnson
Harvard Business School
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.